IOVA has climbed more than 400% from its low. Can lung cancer turn Amtagvi into a much bigger franchise?
Iovance approaches new lung cancer data as Amtagvi revenue hits $91 million and IOVA trades near a 52-week high after a major 2026 rally.
Pharma & Biotech
Pharma & Biotech
Replimune survived two FDA rejections and won the panel vote. Why RP1’s hardest question remains unanswered
Replimune Group is awaiting a delayed FDA decision on RP1 after advisers voted that its melanoma results were clinically meaningful. Approval would create a more accessible oncolytic immunotherapy option, but regulators remain divided over whether the single-arm IGNYTE trial reliably proves RP1’s contribution.
Pharma & Biotech
Tudriqev approval after two FDA rejections turns an engineered herpes virus into a melanoma treatment
The United States Food and Drug Administration (FDA) has granted accelerated approval to Replimune Group’s Tudriqev in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed during a programmed death receptor-1 blocking treatment. The August 6, 2026 decision gives oncologists a new option for a difficult stage of melanoma treatment, when tumours
Pharma & Biotech
What the Obsidian Therapeutics and Galera Therapeutics merger means for OBX-115
Obsidian Therapeutics closes its Galera merger and $350 million financing, putting OBX-115 melanoma data and execution under investor scrutiny.